A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma

Protocol No
ADCT-301-201-HL
Principal Investigator
Mehdi Hamadani
Phase
II
Summary
The purpose of this study is to find out whether the new drug, camidanlumab tesirine, reduces the symptoms of Hodgkin Lymphoma, and whether it causes any problems (side effects).
Description
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: